Anglo-Swedish drugmaker (LSE: AZN) has entered into agreements with privately-held Danish drugmaker LEO Pharma that support its strategic focus on three main therapy areas; respiratory, inflammation and autoimmunity, cardiovascular and metabolic disease and oncology.
The agreements include two of AstraZeneca’s potential new medicines for dermatitis and psoriasis, allowing the company to further simplify and sharpen focus on innovative new medicines in the main therapy areas.
Agreement for tralokinumab for dermatology with LEO
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze